Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Favicovir vs Avigan in Healthy Volunteers
NCT04406194Phase 1Completed
- Sponsor
- Atabay Kimya
- Start
- May 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of favipiravir in influenza and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Atabay Kimya. Primary endpoints: Area Under the Curve from time 0 to the last measurable concentration and Maximum Plasma Concentration. Started May 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04406194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04406194.